S
SUMMIT THERAPEUTICS PLC
NASDAQ: SMMT (Summit Therapeutics Inc.)
Kemas kini terakhir: 3 jam lalu19.67
0.36 (1.86%)
| Penutupan Terdahulu | 19.31 |
| Buka | 19.31 |
| Jumlah Dagangan | 2,487,560 |
| Purata Dagangan (3B) | 2,677,718 |
| Modal Pasaran | 15,251,580,928 |
| Harga / Buku (P/B) | 22.72 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2026 |
| EPS Cair (TTM) | -0.340 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.87% |
| Nisbah Semasa (MRQ) | 10.63 |
| Aliran Tunai Operasi (OCF TTM) | -173.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -104.80 M |
| Pulangan Atas Aset (ROA TTM) | -52.50% |
| Pulangan Atas Ekuiti (ROE TTM) | -123.93% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Summit Therapeutics Inc. | Menurun | Bercampur |
AISkor Stockmoo
0.6
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.63 |
|
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 84.32% |
| % Dimiliki oleh Institusi | 13.52% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Polymer Capital Management (Hk) Ltd | 31 Dec 2025 | 1,421,155 |
| Apeiron Capital Ltd | 31 Dec 2025 | 1,309,241 |
| Td Asset Management Inc | 31 Dec 2025 | 1,205,272 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (Citizens, 103.36%) | Beli |
| Median | 35.00 (77.94%) | |
| Rendah | 30.00 (HC Wainwright & Co., 52.52%) | Beli |
| Purata | 35.00 (77.94%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 15.30 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Feb 2026 | 30.00 (52.52%) | Beli | 16.12 |
| 02 Feb 2026 | 40.00 (103.36%) | Beli | 14.06 | |
| Citizens | 30 Jan 2026 | 40.00 (103.36%) | Beli | 14.48 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |